» Articles » PMID: 21463276

Neuroimaging and Neuropathology of Dravet Syndrome

Overview
Journal Epilepsia
Specialty Neurology
Date 2011 Apr 6
PMID 21463276
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Brain magnetic resonance imaging (MRI) studies in patients with Dravet syndrome and SCN1A mutations have shown abnormal findings in a small minority of patients. The origin of the structural abnormalities--such focal brain atrophy, cortical dysplasia, and hippocampal sclerosis--observed in some children remains unclear. There seems to be no correlation between the presence of MRI abnormalities and duration of epilepsy, age at seizure onset, or the frequency of episodes of status epilepticus having occurred early in life. Recent descriptions of Rasmussen syndrome and of the hemiconvulsion-hemiplegia syndrome in isolated patients with SCN1A mutations are of uncertain meaning but might indicate that co-occurring immunomediated or seizure-induced structural changes can, in turn, become a substrate for the severe epileptic encephalopathy. The few available neuropathologic studies of Dravet syndrome have provided inconsistent findings, including evidence of subtle brain malformation. However, the underlying dysfunction of the SCN1A gene might confer to the brain a unique profile of vulnerability whose consequences are not easily disclosed by neuropathology and require specific experimental settings to be fully appreciated. There would seem to be value in studies in animal models of these aspects, as well as prospective studies in humans, with a particular view to establishing if earlier diagnosis and efforts at seizure control may influence the development of any clinical, imaging, or pathologic deterioration.

Citing Articles

Low-dose fenfluramine as an effective treatment option for 'atypical' Dravet syndrome.

Iguchi A, Yamaguchi T, Yabe T, Miyashita M, Mizutani S, Otani H Epilepsy Behav Rep. 2024; 28:100714.

PMID: 39430947 PMC: 11489070. DOI: 10.1016/j.ebr.2024.100714.


Expanding the Mutational Landscape and Clinical Phenotype of CHD2-Related Encephalopathy.

Clara-Hwang A, Stefani S, Lau T, Scala M, Aynekin B, Bernardo P Neurol Genet. 2024; 10(4):e200168.

PMID: 39035822 PMC: 11259532. DOI: 10.1212/NXG.0000000000200168.


Dravet Syndrome: A Rare Form of Epilepsy.

Hosani S, Varghese S Case Rep Med. 2024; 2024:6710512.

PMID: 38983583 PMC: 11233182. DOI: 10.1155/2024/6710512.


Phenotypic features of epilepsy due to sodium channelopathies - A single center experience from India.

Viswanathan L, Alapati S, Nagappa M, Mundlamuri R, Kenchaiah R, Asranna A J Neurosci Rural Pract. 2023; 14(4):603-609.

PMID: 38059254 PMC: 10696347. DOI: 10.25259/JNRP_329_2023.


Fenfluramine increases survival and reduces markers of neurodegeneration in a mouse model of Dravet syndrome.

Cha J, Filatov G, Smith S, Gammaitoni A, Lothe A, Reeder T Epilepsia Open. 2023; 9(1):300-313.

PMID: 38018342 PMC: 10839300. DOI: 10.1002/epi4.12873.